William Blair Has Positive Forecast for Hologic Q3 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at William Blair lifted their Q3 2025 earnings per share estimates for shares of Hologic in a note issued to investors on Thursday, February 6th. William Blair analyst A. Brackmann now anticipates that the medical equipment provider will post earnings of $1.12 per share for the quarter, up from their prior estimate of $1.10. William Blair has a “Outperform” rating on the stock. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. William Blair also issued estimates for Hologic’s Q4 2025 earnings at $1.10 EPS, Q1 2026 earnings at $1.11 EPS, Q2 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.17 EPS and FY2026 earnings at $4.55 EPS.

Other equities analysts have also issued research reports about the company. Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. UBS Group lifted their price objective on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Jefferies Financial Group began coverage on Hologic in a research note on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target for the company. Finally, Evercore ISI cut their price target on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday. Ten investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $85.77.

Hologic Stock Performance

NASDAQ HOLX opened at $65.45 on Friday. The stock has a 50-day simple moving average of $72.63 and a two-hundred day simple moving average of $77.86. The firm has a market capitalization of $14.77 billion, a P/E ratio of 19.65, a PEG ratio of 2.35 and a beta of 0.98. Hologic has a fifty-two week low of $64.87 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.88% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Hologic

Several institutional investors have recently bought and sold shares of HOLX. Wolff Wiese Magana LLC acquired a new position in shares of Hologic during the 3rd quarter worth approximately $25,000. General Partner Inc. acquired a new position in shares of Hologic during the 4th quarter worth approximately $26,000. Venturi Wealth Management LLC boosted its holdings in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the last quarter. Finally, Cromwell Holdings LLC boosted its holdings in shares of Hologic by 330.2% during the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 416 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.